On June 11, 2014, MediciNova, Inc. (NASDAQ:MNOV), a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced positive results from a study that examined the potential clinical efficacy of MN-001 (tipelukast) for the treatment of pulmonary fibrosis. MediciNova, Inc. (NASDAQ:MNOV), net profit margin is -66.70% and weekly performance is 3.63%. On last trading day company shares ended up $2.00. Analysts mean target price for the company is $6.00. MediciNova, Inc. (NASDAQ:MNOV), distance from 50-day simple moving average (SMA50) is 3.76%.
On June 13, 2014, Cesca Therapeutics Inc (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, announced that it priced an underwritten public offering of 7.53 million Units, consisting of an aggregate of 7.53 million shares of the Company’s common stock and warrants to purchase 2.26 million shares of the Company’s common stock, at a price of $1.50 per Unit. Cesca Therapeutics Inc (NASDAQ:KOOL), fell 2.78% in last trading session and ended the day on $1.40. KOOL, Gross Margin is 36.80% and its return on assets is -34.00%. Cesca Therapeutics Inc (NASDAQ:KOOL), quarterly performance is -17.65%.
Pro-Dex Inc (NASDAQ:PDEX), shares moved up 4.23% in last trading session and was closed at $2.22, while trading in range of $2.05 – 2.32. Pro-Dex Inc (NASDAQ:PDEX), year to date (YTD) performance is -8.64%.
Nature’s Sunshine Prod. (NASDAQ:NATR), a leading natural health and wellness company engaged in the manufacture and direct selling of nutritional and personal care products, and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196-SH 2196.HK), a leading healthcare company in the People’s Republic of China (“China”), announced the signing of definitive agreements with respect to the formation of a China joint venture to market and distribute Nature’s Sunshine and Synergy products in China and an investment by Fosun Pharma of approximately $46.3 million in Nature’s Sunshine common stock to be issued pursuant to a private placement transaction. Nature’s Sunshine Prod. (NASDAQ:NATR), ended the last trading day at $16.71. Company weekly volatility is calculated as 4.38% and price to cash ratio as 3.68. Nature’s Sunshine Prod. (NASDAQ:NATR), showed a negative weekly performance of 17.07%.
On June 13, 2014, Natural Alternatives International, Inc. (NASDAQ:NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced net income of $622,000 or $0.09 per diluted share on net sales of $19.1 million for the quarter ended March 31, 2014. Natural Alternatives International, Inc. (NASDAQ:NAII), net profit margin is 2.20% and weekly performance is -10.31%. On last trading day company shares ended up $5.22. Natural Alternatives International, Inc. (NASDAQ:NAII), distance from 50-day simple moving average (SMA50) is -8.94%.